Thierry Bernard

QIAGEN is the global leader in sample preparation technology — the critical first step in virtually any molecular biology workflow. Before DNA or RNA can be sequenced, amplified by PCR, or otherwise analyzed, it must be extracted and purified from a biological sample (blood, tissue, saliva). QIAGEN's kits and instruments perform this extraction step for customers ranging from hospital diagnostic labs to pharmaceutical R&D departments to forensic crime labs. QIAGEN experienced extraordinary demand during the COVID-19 pandemic, as its RNA extraction kits were essential components of PCR testing workflows worldwide. Managing the post-pandemic normalization — where COVID-related revenue declined sharply — has been a key challenge for Bernard. He has focused on growing non-COVID molecular diagnostics, particularly the QIAstat-Dx syndromic testing platform (which can test for multiple pathogens simultaneously from a single sample), expanding the QuantiFERON tuberculosis testing franchise, and developing digital PCR capabilities. Key stock drivers include non-COVID organic revenue growth, QIAstat-Dx adoption in hospitals, QuantiFERON growth as tuberculosis screening expands globally, bioinformatics and digital health developments, and the overall pace of molecular diagnostics adoption in routine clinical care.